DJE Kapital AG Acquires 2,770 Shares of Johnson & Johnson $JNJ

DJE Kapital AG boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 14.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,134 shares of the company’s stock after acquiring an additional 2,770 shares during the period. DJE Kapital AG’s holdings in Johnson & Johnson were worth $3,365,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock worth $38,800,371,000 after buying an additional 1,170,120 shares during the period. Northern Trust Corp lifted its position in Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock worth $5,131,723,000 after acquiring an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after acquiring an additional 620,039 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Johnson & Johnson by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Johnson & Johnson by 2.5% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock worth $3,031,955,000 after purchasing an additional 448,666 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.3%

JNJ opened at $186.50 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a 50-day simple moving average of $184.25 and a 200 day simple moving average of $168.70. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $449.34 billion, a price-to-earnings ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Bank of America upped their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research report on Monday, October 20th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.